Giulia Notini

MD | Oncology Resident at San Raffaele Hospital, Milan | Now based in Barcelona at IBCC | Part of the scientific team of MEDSIR

[Giulia Notini @NotiniGiulia]

🧵 1/10

Do you know everything about Trop2? 🤔

In this pan-cancer multi-omic analysis, we explored TACSTD2 expression, regulation, and biological associations across normal tissues and tumor types.

🔗https://t.co/WhTZRfT62R

[Giampaolo Bianchini @BianchiniGP]

🔥 Trop 2 pan-cancer, normal tissue and single cell expression analysis just out in NPJ precision oncology

Tissue distribution explain on-target off-tumor side effects such as mucositis

Methylation is key regulatory mechanism

More 👇👇👇
@OncoAlert @Larvol
@NaturePortfolio

[Giulia Notini @NotiniGiulia]

🙏🙏 @MatteoMNaldini , @CarloBoMD , @gdemicheli1 , @LLicata88 , @mariani_m97 , Marta Piras, @CarmenCriscit , Marco Barreca, @mauricallari , Caterina Zanibelli, Francesca Patané, @anto_chiavassa , José Perez-García, @HRazaAliLab , @JavierCortesMD , @lajos_pusztai and Luca Gianni

[Giulia Notini @NotiniGiulia]

🧵 1/10

Do you know everything about Trop2? 🤔

In this pan-cancer multi-omic analysis, we explored TACSTD2 expression, regulation, and biological associations across normal tissues and tumor types.

🔗https://t.co/WhTZRfT62R

[Giulia Notini @NotiniGiulia]

🧵10/10

This was truly a team effort.

Special thanks to my mentor @BianchiniGP , Barbara Galbardi, @giu_viale , @DugoMat , @GileadSciences for supporting this project through an unrestricted research grant, and @MyUniSR & @SanRaffaeleMI

Many thanks also to all co-authors! 👇

[Giampaolo Bianchini @BianchiniGP]

🔥 Who truly benefits from immune checkpoint inhibitors in early triple-negative breast cancer (#TNBC)?
Precision immunology is a major unmet need
✅Key finding: on-treatment complement baseline biopsies
Immunity is dynamic, not a snapshot
Link and more 👇👇👇
@Annals_Oncology

[Annals of Oncology @Annals_Oncology]

📣De-escalation strategies in HER2+ EBC aim at reducing treatment toxicity without compromising efficacy
PHERGain-2 tested a pCR-guided de-escalation to omit CT in selected patients, and resulted in HRQoL preservation and pCR rate like standard CT + HP
https://t.co/rF8aTFK7fS

[Giulia Notini @NotiniGiulia]

My personal highlight from #EsmoBreast2026 (which I'll remember forever!).
Thank you @JavierCortesMD for being exactly who you are (including the Paul the Octopus substitute). Very lucky to learn from brilliant people who manage to make this job both inspiring and fun ❤️

[Giulia Notini @NotiniGiulia]

ADCs are reshaping breast cancer care, but enthusiasm alone is not a strategy.

In our new @PLOSMedicine Perspective, with my mentors (the actual dream team), we dig into some of the big challenges in modern ADC development.

Thoughts? 💭

@BianchiniGP @JavierCortesMD
👇👇

[Irene Persano @IPersano_]

A key topic of debate on early #breastcancer is how will the choice of adjuvant #CDKi, #PARPi and ChT change in the context of emerging de-escalation strategies for axillary surgery.
We discuss this in our work on Cancer Treatment Reviews.

https://t.co/tAJN3op0A4

@BianchiniGP

[Giampaolo Bianchini @BianchiniGP]

Couldn’t be prouder of @MatteoMNaldini for receiving the ESMO Research Fellowship 2025! 🌟
You’ve worked incredibly hard and truly earned this.
Deep thanks to @myESMO for always believing in and supporting the next generation of physician-scientists.

[Luca Licata, MD @LLicata88]

📣Another step forward for #precision_immunotherapy in breast cancer!

🚀Just out in @Nature_NPJ Breast Cancer our exploratory analysis of the NeoTRIP trial showing the role of tumor-specific MHC-II as a predictor of immunotherapy benefit in #TNBC.

📌https://t.co/UVIAAifv8t

[Giampaolo Bianchini @BianchiniGP]

🔥Impressed by PATINA trial results?
👉 the longest mPFS ever in breast cancer (44 mths)

Unexpected? Not really
- Our study (👇👇) explain the biological rational
- Supportive clinical trials (NA-PHER2, PERTAIN)

❗️CLEOPATRA trial did not allow ET maintenance

@SABCSSanAntonio